Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $4.00

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) have been assigned a consensus rating of “Hold” from the five research firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $4.00.

A number of brokerages have recently issued reports on MCRB. The Goldman Sachs Group cut their price objective on shares of Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating on the stock in a research report on Friday. StockNews.com raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 6th.

Institutional Trading of Seres Therapeutics

Several large investors have recently bought and sold shares of the stock. FMR LLC grew its position in Seres Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after purchasing an additional 140,096 shares during the last quarter. Millennium Management LLC lifted its stake in Seres Therapeutics by 77.2% during the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock valued at $1,505,000 after acquiring an additional 788,762 shares during the period. Geode Capital Management LLC lifted its stake in Seres Therapeutics by 8.8% during the 4th quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock valued at $1,256,000 after acquiring an additional 121,793 shares during the period. Vontobel Holding Ltd. lifted its stake in Seres Therapeutics by 137.6% during the 4th quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock valued at $780,000 after acquiring an additional 543,469 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Seres Therapeutics by 15.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock valued at $720,000 after acquiring an additional 117,107 shares during the period. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Stock Up 8.1 %

Shares of Seres Therapeutics stock opened at $0.69 on Friday. The firm’s 50 day moving average price is $0.79 and its 200-day moving average price is $0.83. Seres Therapeutics has a 52-week low of $0.54 and a 52-week high of $1.53. The company has a market cap of $120.10 million, a P/E ratio of -3.00 and a beta of 2.19.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.